Sequenom study shows potential for single-platform genetic tests

By Elaine Rigoli

Tampa, Fla., March 27 - Sequenom, Inc. announced Monday that two proof-of-concept molecular diagnostic studies using the MassArray system yielded absolute equivalence of analytical results generated by the MassArray Compact system when compared with well-established systems in current use.

The studies tested for cystic fibrosis (CFTR) and for Factor V Leiden, a marker associated with predisposition for deep vein thrombosis, according to a news release.

"The analytical results generated in our laboratory from CFTR and Factor V Leiden testing using Sequenom's MassArray system were 100% in agreement with the results we generated using a well-established competing technology," Specialty chief science officer James B. Peter said in the release.

"The MassArray system demonstrated clear benefits, including rapid assay design, high throughput and platform flexibility. These benefits contribute to the overall cost-effectiveness of the platform."

As the number of diseases that incorporate genetic analysis into patient management increases, the opportunity for MassArray technology in development of molecular diagnostics becomes greater, officials said.

The data also indicated technical advantages for the development and commercialization of non-invasive prenatal diagnostic tests.

Sequenom, based in San Diego, develops genetic analysis products for non-invasive prenatal testing, biomedical research, molecular medicine and agricultural applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.